PILL:NYE-Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF (USD)

ETF | Trading--Leveraged Equity |

Last Closing

USD 9.09

Change

+0.19 (+2.13)%

Market Cap

N/A

Volume

0.07M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-05 )

Largest Industry Peers for Trading--Leveraged Equity

Symbol Name Price(Change) Market Cap
SOXL Direxion Daily Semiconductor B..

+1.03 (+3.39%)

USD 11.35B
QLD ProShares Ultra QQQ

+2.53 (+2.55%)

USD 7.34B
FNGU MicroSectors FANG+ Index 3X Le..

+22.66 (+5.27%)

USD 5.84B
SSO ProShares Ultra S&P500

+2.11 (+2.39%)

USD 5.40B
UPRO ProShares UltraPro S&P500

+3.00 (+3.61%)

USD 4.05B
TECL Direxion Daily Technology Bull..

+3.49 (+4.19%)

USD 3.15B
YINN Direxion Daily FTSE China Bull..

+2.38 (+7.01%)

USD 2.18B
USD ProShares Ultra Semiconductors

+5.90 (+4.62%)

USD 1.31B
LABU Direxion Daily S&P Biotech Bul..

+5.23 (+4.10%)

USD 0.91B
DPST Direxion Daily Regional Banks ..

+5.50 (+5.25%)

USD 0.74B

ETFs Containing PILL

N/A

Market Performance

  Market Performance vs. Industry/Classification (Trading--Leveraged Equity) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1,659.35% 94% A 98% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 1,659.35% 94% A 98% N/A
Trailing 12 Months  
Capital Gain 2,361.19% 94% A 99% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 2,361.19% 94% A 99% N/A
Trailing 5 Years  
Capital Gain 813.94% 91% A- 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 813.94% 91% A- 96% N/A
Average Annual (5 Year Horizon)  
Capital Gain 38.72% 70% C- 91% A-
Dividend Return 39.22% 70% C- 91% A-
Total Return 0.49% 38% F 12% F
Risk Return Profile  
Volatility (Standard Deviation) 325.11% 15% F 3% F
Risk Adjusted Return 12.06% 24% F 31% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.